Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics Inc. reported an amended insider transaction for its President, CEO and director, Jack W. Callicutt. On January 16, 2026, he was granted a stock option to buy 91,000 shares of common stock at an exercise price of $3.04 per share under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The option vests in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expires on January 16, 2036. Following this grant, Callicutt directly holds 91,000 derivative securities in the form of these options. This Form 4/A corrects the originally filed number of options previously reported on January 21, 2026.
Galectin Therapeutics director Carson Benjamin Sr reported an award of stock options under the company’s 2019 Omnibus Equity Incentive Plan. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, recorded at a price of $0 for the grant itself. These options give the right to buy Galectin Therapeutics common stock and are held as direct ownership.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date and remain outstanding until their expiration on January 16, 2036. Following this grant, Benjamin beneficially owns 60,000 derivative securities in the form of these stock options.
Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.
The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.
Galectin Therapeutics Inc. director Richard A. Zordani Jr. reported a grant of stock options on common shares. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Zordani beneficially owns 60,000 derivative securities directly in the form of these options, providing potential future ownership of the same number of Galectin common shares if exercised.
Galectin Therapeutics reported new equity awards to its Chief Medical Officer, Jamil Khurram. On January 16, 2026, Khurram received stock options covering 65,000 shares of common stock with an exercise price of
On the same date, Khurram was also granted 100,000 Restricted Stock Units under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. These RSUs vest 100% on the earlier of
Galectin Therapeutics director Kevin D. Freeman reported a new stock option award. On January 16, 2026, he was granted a stock option (right to buy) covering 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share.
The option was issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026. Following this grant, Freeman beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics director Kary Eldred received a new stock option grant. On January 16, 2026, Eldred was awarded options to purchase 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share. These options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026, meaning they become fully exercisable on that date. The options expire on January 16, 2036 if not exercised. Following this grant, Eldred beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics Inc. reported new equity awards for its President and CEO, Lewis Joel, who also serves as a director. On January 16, 2026, he was granted 84,000 stock options with an exercise price of $3.04 per share under the company’s 2019 Omnibus Equity Incentive Plan. The options vest in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, Joel also received 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. Each vested RSU converts into one share of Galectin common stock.
Galectin Therapeutics Inc. Chief Financial Officer Jack W. Callicutt reported new equity awards from the company. On January 16, 2026, he received a stock option for 65,000 shares of common stock at an exercise price of $3.04 per share, expiring on January 16, 2036. The options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, he was also granted 100,000 Restricted Stock Units. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. All awards were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, and are reported as directly owned by the officer.
Galectin Therapeutics Inc. granted stock options to a board member. Director Harold H. Shlevin received stock options covering 60,000 shares of Galectin Therapeutics common stock on January 16, 2026. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and expire on January 16, 2036. The options vest 100% on December 31, 2026, meaning Shlevin must remain eligible through that date before they become fully exercisable. Following this grant, he beneficially owns 60,000 derivative securities, held directly.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
